Project Updates
BIOVECTRA
Credit: BIOVECTRA
Location: Charlottetown, Prince Edward Island, Canada
Project type: mRNA Vaccine and Biomanufacturing Centre
Announced: November 2021
Construction Started: April 2022
BIOVECTRA, a biotech and pharmaceutical company, is building a new facility to produce and manufacture messenger ribonucleic acid (mRNA) vaccines and therapeutics at its Charlottetown campus in Canada.
AGC Biologics
Credit: AGC Biologics
Location: Heidelberg, Germany
Project type: Manufacturing Facility Expansion
Announced: September 2021
Completion: October 2023
AGC Biologics (AGC), a contract development and manufacturing organisation (CDMO) based in the US, has expanded its facility in Heidelberg, Germany, to increase its plasmid DNA (pDNA) and messenger RNA (mRNA) manufacturing capabilities.
Novo Nordisk
Credit: Novo Nordisk
Location: Kalundborg, Denmark
Project type: Active pharmaceutical ingredients (API) manufacturing facility
Estimated Investment: More than DKr42bn ($6bn)
Area: 170,000m²
Novo Nordisk, a pharmaceutical company based in Denmark, announced plans in November 2023 to expand its existing manufacturing capacity by building a new active pharmaceutical ingredients (API) facility in Kalundborg, Denmark.
